Abstract
Background
Brain natriuretic peptide (BNP) level has emerged as a predictor of death and hospital readmission in patients with heart failure (HF). The value of baseline BNP assessment in advanced HF patients receiving cardiac resynchronization defibrillator therapy (CRT‐D) has not been firmly established.
Hypothesis
We hypothesized that a baseline BNP level would predict all cause mortality and HF hospitalization in HF patients receiving cardiac resynchronization therapy.
Methods
A retrospective chart review of all patients having BNP assessment prior to implantation of a CRT‐D for standard indications during 2004 and 2005 was conducted at the Veterans Affairs Pittsburgh Healthcare System. The primary endpoint was all‐cause mortality and the secondary endpoint was HF‐related hospitalization. We used findings from the receiver operating characteristic (ROC) curve to define low (<492 pg/mL) and high (≥492 pg/mL) BNP groups.
Results
Out of 173 CRT‐D recipients, 115 patients (mean age 67.0 ± 10.7 years, New York Heart Association [NYHA] class 2.9 ± 0.3, left ventricular ejection fraction [LVEF] 22.5% ± 9.6%, QRS 148.3 ± 30.4 ms) had preimplantation BNP measured (mean 559 ± 761 pg/mL and median 315 pg/mL). During a mean follow‐up time of 17.5 ± 6.5 mo, 27 deaths (23.5%) and 31 HF hospitalizations (27.0%) were recorded. Compared to those with low BNP (n = 74), those of high BNP (n = 41) were older, had lower LVEF, higher creatinine levels, suffered more deaths, and HF hospitalizations. In multivariate regression models, higher BNP remained a significant predictor of both the primary endpoint (hazard ratio [HR]: 2.89, 95% confidence interval [CI] 1.06–7.88, p = 0.038) and secondary endpoint (HR: 4.23, 95% CI: 1.68–10.60, p = 0.002).
Conclusions
Baseline BNP independently predicted mortality and HF hospitalization in a predominantly older white male population of advanced HF patients receiving CRT‐D. Elevated BNP levels may identify a vulnerable HF population with a particularly poor prognosis despite CRT‐D. Copyright © 2009 Wiley Periodicals, Inc.
Keywords: Brain natriuretic peptide, cardiac resynchronization therapy, mortality, heart failure
Full Text
The Full Text of this article is available as a PDF (126.3 KB).
References
- 1. Balion C, Santaguida P, Hill S, Worster A, McQueen M, et al.: Testing for BNP and NT‐proBNP in the diagnosis and prognosis of heart failure. Evidence Report/Technology Assessment No. 142. The Agency for Healthcare Research and Quality (AHRQ), Publication No. 06‐E014. Rockville, MD; 2006; September. [PMC free article] [PubMed]
- 2. Lellouche N, De Diego C, Cesario D, Vaseghi M, Horowitz B, et al.: Usefulness of preimplantation B‐type natriuretic peptide level for predicting response to cardiac resynchronization therapy. Am J Cardiol 2007; 99: 242–246. [DOI] [PubMed] [Google Scholar]
- 3. Pitzalis MV, Iacoviello M, Di Serio F, Romito R, Guida P, et al.: Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy. Eur J Heart Fail 2006; 8: 509–514. [DOI] [PubMed] [Google Scholar]
- 4. Richardson M, Freemantle N, Calvert MJ, Cleland JG, Tavazzi L: Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: A pre‐defined analysis from the CARE‐HF trial. Eur Heart J 2007; 15: 1827–1834. [DOI] [PubMed] [Google Scholar]
- 5. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C: Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91–96. [DOI] [PubMed] [Google Scholar]
- 6. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, et al.: Predischarge B‐type natriuretic peptide assay for identifying patients at high risk of re‐admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641. [DOI] [PubMed] [Google Scholar]
- 7. Boriani G, Regoli F, Saporito D, Martignani C, Toselli T, et al.: Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides 2006; 27: 1776–1786. [DOI] [PubMed] [Google Scholar]
- 8. Hernandez Madrid A, Miguelanez Diaz M, Escobar Cervantes C, Blanco Tirados B, Marin I, et al.: [Usefulness of brain natriuretic peptide to evaluate patients with heart failure treated with cardiac resynchronization]. Rev Esp Cardiol 2004; 57: 299–305. [PubMed] [Google Scholar]
- 9. Delgado RM, Palanichamy N, Radovancevic R, Vrtovec B, Radovancevic B: Brain natriuretic peptide levels and response to cardiac resynchronization therapy in heart failure patients. Congest Heart Fail 2006; 12: 250–253. [DOI] [PubMed] [Google Scholar]
- 10. Kubanek M, Malek I, Bytesnik J, Fridl P, Riedlbauchova L, et al.: Decrease in plasma B‐type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fail 2006; 8: 832–840. [DOI] [PubMed] [Google Scholar]
- 11. Glick A, Michowitz Y, Keren G, George J: Neurohormonal and inflammatory markers as predictors of short‐term outcome in patients with heart failure and cardiac resynchronization therapy. Isr Med Assoc J 2006; 8: 391–395. [PubMed] [Google Scholar]
- 12. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN: QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002; 143: 1085–1091. [DOI] [PubMed] [Google Scholar]
- 13. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, et al.: Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long‐term treatment with beta‐blockers: results from COMET. Eur Heart J 2005; 26: 1303–1308. [DOI] [PubMed] [Google Scholar]
- 14. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, et al.: Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006; 114: 2766–2772. [DOI] [PubMed] [Google Scholar]